A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION US VC Coalition Urges Japan to Rethink Drug Pricing, Labor Rules
October 13, 2026
-
REGULATORY Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
-
BUSINESS TOPIX Shuffle Puts Mid-Tier Drug Makers, Wholesalers on Chopping Block
October 9, 2026
-
REGULATORY Provider-Payer Tug-of-War Takes Shape over FY2027 Drug Price Revision
October 8, 2026
-
ACADEMIA HPV Expert Backs Routine Shots for Males, Urges Broader Assessment
October 7, 2026
-
ORGANIZATION PhRMA Taps Jonathan Kushner as New Japan Representative
October 6, 2026
-
BUSINESS LinDo Sets Sights on More Pediatric Deals as It Builds Drug-Loss Portfolio
October 6, 2026
-
BUSINESS Shionogi to Buy IntraBio for US$2 Billion, Gains Rare Disease Drug
October 6, 2026
-
REGULATORY Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
-
BUSINESS Gilead Paints Sustained Growth Curve with Trodelvy, CAR-T Therapies
October 2, 2026
-
REGULATORY Chuikyo Backs Broader CEA Price Cuts This Year, Snubs Pharma Plea
October 1, 2026
-
REGULATORY CEA Transparency Gains Welcome, but Guidelines Need Scrutiny: Economist
September 30, 2026
-
REGULATORY More Company Involvement in CEA a Big Positive: C2H Researcher
September 29, 2026
-
COMMENTARY Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
September 28, 2026
-
ORGANIZATION JaDHA Calls for Digital Health Seat in Chuikyo Reform
September 28, 2026
-
ORGANIZATION Digital Health Group Eager to Gain Full Seat at Chuikyo Table
September 25, 2026
-
REGULATORY MHLW Pharma Chief Eyes Wider Use of English Drug Filings to Stem Drug Loss
September 25, 2026
-
BUSINESS Roche Proposes Ex-Takeda CEO Weber for Board
September 24, 2026
-
REGULATORY Pharma Urges Pricing Rewards to Bolster Japan’s Drug Discovery Strength
September 24, 2026
-
REGULATORY Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…